HC Wainwright reaffirmed their buy rating on shares of Pyxis Oncology (NASDAQ:PYXS - Free Report) in a report published on Wednesday, Benzinga reports. The firm currently has a $7.00 price target on the stock.
A number of other research analysts also recently issued reports on PYXS. BTIG Research began coverage on shares of Pyxis Oncology in a research report on Friday, February 9th. They set a buy rating and a $8.00 target price for the company. Royal Bank of Canada reissued an outperform rating and issued a $7.00 price objective on shares of Pyxis Oncology in a report on Friday, March 22nd. Leerink Partnrs restated an outperform rating on shares of Pyxis Oncology in a research note on Tuesday, January 23rd. Finally, SVB Leerink began coverage on Pyxis Oncology in a research report on Tuesday, January 23rd. They set an outperform rating and a $12.00 price target for the company. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of Buy and an average target price of $8.50.
View Our Latest Stock Report on PYXS
Pyxis Oncology Trading Down 5.0 %
NASDAQ PYXS traded down $0.27 on Wednesday, hitting $5.08. 664,494 shares of the company's stock traded hands, compared to its average volume of 845,125. The firm's 50-day moving average price is $5.01 and its two-hundred day moving average price is $3.02. The firm has a market capitalization of $295.30 million, a PE ratio of -2.73 and a beta of 1.51. Pyxis Oncology has a 1-year low of $1.35 and a 1-year high of $6.85.
Hedge Funds Weigh In On Pyxis Oncology
Several institutional investors and hedge funds have recently modified their holdings of the business. Tower Research Capital LLC TRC boosted its position in Pyxis Oncology by 75.9% during the first quarter. Tower Research Capital LLC TRC now owns 10,866 shares of the company's stock worth $43,000 after purchasing an additional 4,688 shares in the last quarter. Dimensional Fund Advisors LP purchased a new position in Pyxis Oncology in the 1st quarter valued at about $48,000. Goldman Sachs Group Inc. acquired a new stake in Pyxis Oncology in the 2nd quarter worth about $31,000. Commonwealth Equity Services LLC purchased a new stake in Pyxis Oncology during the 3rd quarter worth approximately $26,000. Finally, Acadian Asset Management LLC acquired a new position in shares of Pyxis Oncology during the third quarter valued at approximately $26,000. Hedge funds and other institutional investors own 39.09% of the company's stock.
About Pyxis Oncology
(
Get Free Report)
Pyxis Oncology, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma.
See Also
Before you consider Pyxis Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pyxis Oncology wasn't on the list.
While Pyxis Oncology currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
